Furthermore, Zheng et al. found that the KLF12−Gal-1 axis might serve as a novel therapeutic target, as decreased KLF12 and increased Gal-1 expression were associated with resistance to anti-PD-1 immunotherapy in various mouse tumor models. Here, GAL is linked to neoplasm.